Nitecapone

Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation . In Vitro Nitecapone (1-100 μM) reducesd GSH (reduced glutathione) depletion induced by ROO - by 11-38% and oxidation to oxidized glutathione (GSSG) by 32-45%. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Nitecapone (30 mg/kg, ip daily for 13 days) reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eighty-six male Wistar rats, weighing 140-350 g. Dosage: 30 mg/kg (3.3 mL/kg). Administration: IP, once daily for 13 days. Result: Selectively and specifically inhibits COMT in the peripheral tissues, and to some extent in the CNS for ca. 3 h. Increased the thresholds for the mechanical stimuli and thus reduced mechanical allodynia. Reduced the number of positive reactions of the ipsilateral paws when compared with the baselines in the nitecapone-pretreated rats.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet